Zhongji Liao1, Joseph M Cantor2. 1. From the Department of Medicine, University of California San Diego, La Jolla. 2. From the Department of Medicine, University of California San Diego, La Jolla. jmcantor@ucsd.edu.
Abstract
OBJECTIVE: CD98 regulates integrin signaling and is critical for tumor cell proliferation. It is also expressed on endothelial cells (EC), but its role in angiogenesis is unclear. APPROACH AND RESULTS: We used specific genetic targeting and antibody blockade approaches to examine the function of CD98 in EC proliferation, blood vessel growth, and tumor angiogenesis. It is upregulated on angiogenic ECs, and EC-specific deletion of CD98 in mice inhibited tumor growth, retinal angiogenesis, and EC proliferation. Reconstitution with CD98 mutants showed that integrin and CD98 interaction is necessary for EC survival and growth. Moreover, anti-CD98 treatment inhibited vessel formation and reversed EC-assisted tumor growth. CONCLUSIONS: Our findings demonstrate a requirement for CD98 in EC growth and suggest that CD98-specific reagents could have a dual anticancer effect: directly by inhibiting tumor cell proliferation and indirectly by preventing tumor angiogenesis.
OBJECTIVE:CD98 regulates integrin signaling and is critical for tumor cell proliferation. It is also expressed on endothelial cells (EC), but its role in angiogenesis is unclear. APPROACH AND RESULTS: We used specific genetic targeting and antibody blockade approaches to examine the function of CD98 in EC proliferation, blood vessel growth, and tumor angiogenesis. It is upregulated on angiogenic ECs, and EC-specific deletion of CD98 in mice inhibited tumor growth, retinal angiogenesis, and EC proliferation. Reconstitution with CD98 mutants showed that integrin and CD98 interaction is necessary for EC survival and growth. Moreover, anti-CD98 treatment inhibited vessel formation and reversed EC-assisted tumor growth. CONCLUSIONS: Our findings demonstrate a requirement for CD98 in EC growth and suggest that CD98-specific reagents could have a dual anticancer effect: directly by inhibiting tumor cell proliferation and indirectly by preventing tumor angiogenesis.
Authors: Chloe C Feral; Naoyuki Nishiya; Csilla A Fenczik; Heidi Stuhlmann; Marina Slepak; Mark H Ginsberg Journal: Proc Natl Acad Sci U S A Date: 2004-12-29 Impact factor: 11.205
Authors: Joseph Cantor; Cecille D Browne; Raphael Ruppert; Chloé C Féral; Reinhard Fässler; Robert C Rickert; Mark H Ginsberg Journal: Nat Immunol Date: 2009-03-08 Impact factor: 25.606
Authors: Deep K Hathi; Elizabeth N DeLassus; Samuel Achilefu; Jonathan McConathy; Monica Shokeen Journal: J Nucl Med Date: 2018-04-26 Impact factor: 10.057
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Martina Šrajer Gajdošik; Anamarija Kovač Peić; Marija Begić; Petra Grbčić; Kate E Brilliant; Douglas C Hixson; Djuro Josić Journal: Int J Mol Sci Date: 2022-08-09 Impact factor: 6.208
Authors: Giulia Pellizzari; Olivier Martinez; Silvia Crescioli; Robert Page; Ashley Di Meo; Silvia Mele; Giulia Chiaruttini; Jan Hoinka; Ihor Batruch; Ioannis Prassas; Melanie Grandits; Jacobo López-Abente; Eva Bugallo-Blanco; Malcolm Ward; Heather J Bax; Elise French; Anthony Cheung; Sara Lombardi; Mariangela Figini; Katie E Lacy; Eleftherios P Diamandis; Debra H Josephs; James Spicer; Sophie Papa; Sophia N Karagiannis Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Rokaya El Ansari; Madeleine L Craze; Maria Diez-Rodriguez; Christopher C Nolan; Ian O Ellis; Emad A Rakha; Andrew R Green Journal: Br J Cancer Date: 2018-03-16 Impact factor: 7.640